"Limited Availability of Lilly's Mounjaro Doses Shown on FDA Website"

The FDA's website indicates limited availability of higher doses of Eli Lilly's diabetes drug, Mounjaro, due to increased demand, with intermittent back orders expected through early March 2024. The company acknowledges the potential disruption in treatment regimens and is working urgently to address the situation. The supply constraints are attributed to soaring demand for GLP-1 agonists, used for diabetes and weight loss, affecting drugmakers like Lilly and Novo Nordisk. Other Mounjaro doses are currently in stock, and both companies are striving to boost production to meet the strong demand.